Protocol summary
-
Study aim
-
The aim of this study is to determine the effects of inofolic supplementation compared with metformin on metabolic profiles in women with polycystic ovary syndrome (PCOS).
-
Design
-
Study design: Parallel clinical trial. Randomization will be done by the use of computer-generated random numbers.
-
Settings and conduct
-
Population and sample size: Among patients with PCOS referred to Kosar Clinic affiliated to Arak University of Medical Sciences, 60 patients will be selected according to inclusion and exclusion criteria.
-
Participants/Inclusion and exclusion criteria
-
Inclusion criteria: Patients with PCOS according to Rotterdam criteria and aged 18–40 years old will be included in this study. Exclusion criteria: Women who were pregnant during the intervention, adrenal hyperplasia, androgen-secreting tumors, hyperprolactinemia, thyroid dysfunction, diabetes or impaired glucose tolerance
-
Intervention groups
-
Intervention: Patients will be assigned into two groups to receive inofolic (n=30) or metformin (n=30).
-
Main outcome variables
-
Outcomes: Total testosterone (primary outcomes), inflammatory factors, and gene expression related to inflammation (secondary outcome) will be quantified at study baseline and end-of-trial.
General information
-
Reason for update
-
-
Acronym
-
-
IRCT registration information
-
IRCT registration number:
IRCT201701295623N105
Registration date:
2017-02-09, 1395/11/21
Registration timing:
retrospective
Last update:
2019-09-25, 1398/07/03
Update count:
1
-
Registration date
-
2017-02-09, 1395/11/21
-
Registrant information
-
-
Recruitment status
-
Recruitment complete
-
Funding source
-
Vice chancellor for research, Arak University of Medical Sciences
-
Expected recruitment start date
-
2016-11-15, 1395/08/25
-
Expected recruitment end date
-
2016-11-30, 1395/09/10
-
Actual recruitment start date
-
empty
-
Actual recruitment end date
-
empty
-
Trial completion date
-
empty
-
Scientific title
-
Clinical trial of the effect of inofolic supplementation compared with metformin on metabolic profiles in women with polycystic ovary syndrome
-
Public title
-
Effect of supplementation in treatment of women with polycystic ovary syndrome
-
Purpose
-
Treatment
-
Inclusion/Exclusion criteria
-
Inclusion criteria:
Patients with PCOS according to Rotterdam criteria.
Aged 18 to 40 years.
Exclusion criteria:
Women who were pregnant during the intervention
Adrenal hyperplasia
Androgen-secreting tumors
Hyperprolactinemia
Thyroid dysfunction
Diabetes or impaired glucose tolerance
-
Age
-
From 18 years old to 40 years old
-
Gender
-
Female
-
Phase
-
3
-
Groups that have been masked
-
No information
-
Sample size
-
Target sample size:
60
-
Randomization (investigator's opinion)
-
Randomized
-
Randomization description
-
Randomization will be done by the use of computer-generated random numbers.
-
Blinding (investigator's opinion)
-
Not blinded
-
Blinding description
-
-
Placebo
-
Used
-
Assignment
-
Parallel
-
Other design features
-
Ethics committees
1
-
Ethics committee
-
-
Approval date
-
2016-11-14, 1395/08/24
-
Ethics committee reference number
-
IR.ARAKMU.REC.1395.309
Health conditions studied
1
-
Description of health condition studied
-
Polycystic ovarian syndrome
-
ICD-10 code
-
E28.2
-
ICD-10 code description
-
Polycystic ovarian syndrome
Primary outcomes
1
-
Description
-
Total testosterone
-
Timepoint
-
At the beginning of the study and after 12 weeks of intervention
-
Method of measurement
-
Elisa kit
Secondary outcomes
1
-
Description
-
Hs-CRP
-
Timepoint
-
At the beginning of the study and after 12 weeks of intervention
-
Method of measurement
-
Elisa kit
2
-
Description
-
Nitric oxide
-
Timepoint
-
At the beginning of the study and after 12 weeks of intervention
-
Method of measurement
-
Spectrophotometry
3
-
Description
-
Expressed levels of LL-1 gene
-
Timepoint
-
At the beginning of the study and after 12 weeks of intervention
-
Method of measurement
-
PCR
4
-
Description
-
Expressed levels of IL-8 gene
-
Timepoint
-
At the beginning of the study and after 12 weeks of intervention
-
Method of measurement
-
PCR
5
-
Description
-
Expressed levels of TNF-a gene
-
Timepoint
-
At the beginning of the study and after 12 weeks of intervention
-
Method of measurement
-
PCR
6
-
Description
-
SHBG
-
Timepoint
-
At the beginning of the study and after 12 weeks of intervention
-
Method of measurement
-
Elisa kit
Intervention groups
1
-
Description
-
Intervention group: Inofolic supplements (Loli, Rome, Italy), 2000 mg myo-inositol, 200 µg folic acid, twice a day, for 12 weeks orally.
-
Category
-
Treatment - Drugs
2
-
Description
-
Control group: Metformin tablet, according to the patient's tolerance, daily for 12 weeks orally.
-
Category
-
Treatment - Drugs
1
-
Sponsor
-
-
Grant name
-
-
Grant code / Reference number
-
-
Is the source of funding the same sponsor organization/entity?
-
Yes
-
Title of funding source
-
Vice chancellor for research, Arak University of Medical Sciences
-
Proportion provided by this source
-
100
-
Public or private sector
-
Public
-
Domestic or foreign origin
-
Domestic
-
Category of foreign source of funding
-
empty
-
Country of origin
-
-
Type of organization providing the funding
-
Academic
Sharing plan
-
Deidentified Individual Participant Data Set (IPD)
-
Undecided - It is not yet known if there will be a plan to make this available
-
Study Protocol
-
Undecided - It is not yet known if there will be a plan to make this available
-
Statistical Analysis Plan
-
Undecided - It is not yet known if there will be a plan to make this available
-
Informed Consent Form
-
Undecided - It is not yet known if there will be a plan to make this available
-
Clinical Study Report
-
Undecided - It is not yet known if there will be a plan to make this available
-
Analytic Code
-
Undecided - It is not yet known if there will be a plan to make this available
-
Data Dictionary
-
Undecided - It is not yet known if there will be a plan to make this available